Specialized CRO Abwiz Bio offers bespoke rabbit monoclonal antibody generation and engineering entirely in-house, focusing on difficult targets such as GPCRs, ion channels, and multi-pass membrane proteins. This positions them as a go-to partner for pharma companies with unsolved targets and low-affinity mouse antibodies.

Proprietary Edge Utilize WizAmp, RabWiz, and STEM technologies to achieve high-affinity, well-characterized antibodies with humanization and maturation all within one platform. Potential buyers can leverage their unique capabilities to accelerate therapeutic antibody programs that struggle with traditional platforms.

In-House IP Control All work is performed in-house with full IP ownership and control, backed by a patent covering their phage display library. This reduces outsourcing risk and offers clients secure, deliverable intellectual property for collaboration and licensing.

Clinical Readiness STEM™ enables affinity maturation and humanization, aligning candidates toward clinical developability. This can shorten lead optimization timelines and improve progression of therapeutic antibody programs.

Growth Opportunities Current revenue range and early-stage funding suggest capacity for expanded partnerships with mid-to-large biopharma and CROs seeking high-affinity antibodies against difficult targets, including collaborations, sponsored programs, or exclusive licensing on niche target portfolios.